ArticleVox sanguinis2026
Red cell alloantibodies in 71,525 Malaysian blood donations: Predominance of anti-Mia reflects GP.Mur-associated antigenic diversity.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesRed cell alloantibody prevalence in blood donors is generally low, but antibody profiles vary according to population antigenic distribution. Data from Southeast Asia remain limited, particularly for antibodies associated with the glycophorin (GP).Mur phenotype. MATERIALS AND
methodsThis retrospective cross-sectional study analysed 71,525 voluntary whole blood donations at a tertiary hospital in Malaysia between 2019 and 2024. Donor demographic and laboratory data were retrieved from the laboratory information system. Antibody screening was performed using the indirect antiglobulin test with in-house pooled screening cells incorporating Mi(a+). Positive samples underwent antibody identification using commercial panels. Univariable logistic regression was used to assess demographic determinants.
resultsOverall alloantibody prevalence was 0.4%. The most frequent specificities were anti-Mia (19.1%) and anti-M (17.5%). Among clinically significant antibodies, anti-Mia accounted for 72.1% (49/68), followed by anti-E, anti-c, anti-S and anti-Diᵃ. Increasing age was associated with higher odds of alloantibody positivity. Discordant antibody profiles were observed in repeat donors, consistent with antibody evanescence.
conclusionDonor alloantibody epidemiology in Malaysia is characterized by a distinct spectrum dominated by anti-Mia, reflecting GP.Mur-associated antigenic diversity. Standard screening panels lacking Mi(a+)-expressing cells may under-detect clinically significant antibodies. Region-specific screening strategies and strengthened haemovigilance systems are required to optimize transfusion safety in Southeast Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.